Galectin Therapeutics (NASDAQ:GALT) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Galectin Therapeutics (NASDAQ:GALT) in a research note released on Friday,Benzinga reports. HC Wainwright currently has a $11.00 price objective on the stock. HC Wainwright also issued estimates for Galectin Therapeutics’ FY2027 earnings at $1.25 EPS and FY2028 earnings at $3.39 EPS.

Separately, StockNews.com cut shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th.

Galectin Therapeutics Price Performance

GALT stock opened at $2.69 on Friday. Galectin Therapeutics has a fifty-two week low of $1.55 and a fifty-two week high of $4.27. The stock has a market capitalization of $167.53 million, a price-to-earnings ratio of -3.68 and a beta of 0.62. The business’s fifty day moving average price is $2.69 and its two-hundred day moving average price is $2.61.

Institutional Trading of Galectin Therapeutics

Large investors have recently modified their holdings of the stock. Marshall Wace LLP bought a new stake in Galectin Therapeutics during the second quarter worth about $43,000. Rhumbline Advisers acquired a new position in shares of Galectin Therapeutics in the 2nd quarter valued at approximately $44,000. Gladstone Institutional Advisory LLC bought a new stake in shares of Galectin Therapeutics during the 3rd quarter worth approximately $60,000. Barclays PLC boosted its position in shares of Galectin Therapeutics by 309.0% during the 3rd quarter. Barclays PLC now owns 28,587 shares of the company’s stock worth $79,000 after acquiring an additional 21,598 shares in the last quarter. Finally, Traynor Capital Management Inc. increased its stake in Galectin Therapeutics by 23.5% in the second quarter. Traynor Capital Management Inc. now owns 42,871 shares of the company’s stock valued at $97,000 after acquiring an additional 8,164 shares during the last quarter. 11.68% of the stock is owned by institutional investors and hedge funds.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.